Search research articles
Contact Us
Filters
Showing results (331-340 of 349) with videos related to
Page
of 35
Sort By:
Neuropharmacology
|
April 1, 1987
Behavioural and biochemical evidence for the release of noradrenaline in mouse brain by TRH and some of its biologically stable analogues
D J Heal, N Stoodley, J M Elliott, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 1, 1997
Iron in the Parkinsonian substantia nigra
M Gerlach, K Double, P Riederer, et al.
Advances in Neurology
|
January 1, 1987
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl
P Riederer, C Konradi, V Schay, et al.
Journal of Neurochemistry
|
February 1, 1989
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
P Riederer, E Sofic, W D Rausch, et al.
Nature
|
March 31, 1972
Human brain monoamine oxidase: multiple forms and selective inhibitors
M B Youdim, G G Collins, M Sandler, et al.
Advances in Neurology
|
January 1, 1993
Iron and ferritin in substantia nigra in Parkinson's disease
K A Jellinger, E Kienzl, G Rumpelmaier, et al.
Neuroscience
|
August 1, 1976
Some histological and metabolic properties of an isolated perfused rat brain preparation with special reference to monoamine metabolism
H F Woods, C W Graham, A R Green, et al.
Neuropharmacology
|
March 1, 1980
The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rats
M B Youdim, A R Green, M R Bloomfield, et al.
Journal of Neurochemistry
|
October 1, 1989
The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B
P Janssens de Varebeke, G Pauwels, C Buyse, et al.
Annals of the New York Academy of Sciences
|
May 28, 1993
The goldfish as a drug discovery vehicle for Parkinson's disease and other neurodegenerative disorders
H B Pollard, M Adeyemo, K Dhariwal, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 349) with videos related to
Sort By:
Page
of 35
Neuropharmacology
|
April 1, 1987
Behavioural and biochemical evidence for the release of noradrenaline in mouse brain by TRH and some of its biologically stable analogues
D J Heal, N Stoodley, J M Elliott, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 1, 1997
Iron in the Parkinsonian substantia nigra
M Gerlach, K Double, P Riederer, et al.
Advances in Neurology
|
January 1, 1987
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl
P Riederer, C Konradi, V Schay, et al.
Journal of Neurochemistry
|
February 1, 1989
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
P Riederer, E Sofic, W D Rausch, et al.
Nature
|
March 31, 1972
Human brain monoamine oxidase: multiple forms and selective inhibitors
M B Youdim, G G Collins, M Sandler, et al.
Advances in Neurology
|
January 1, 1993
Iron and ferritin in substantia nigra in Parkinson's disease
K A Jellinger, E Kienzl, G Rumpelmaier, et al.
Neuroscience
|
August 1, 1976
Some histological and metabolic properties of an isolated perfused rat brain preparation with special reference to monoamine metabolism
H F Woods, C W Graham, A R Green, et al.
Neuropharmacology
|
March 1, 1980
The effects of iron deficiency on brain biogenic monoamine biochemistry and function in rats
M B Youdim, A R Green, M R Bloomfield, et al.
Journal of Neurochemistry
|
October 1, 1989
The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B
P Janssens de Varebeke, G Pauwels, C Buyse, et al.
Annals of the New York Academy of Sciences
|
May 28, 1993
The goldfish as a drug discovery vehicle for Parkinson's disease and other neurodegenerative disorders
H B Pollard, M Adeyemo, K Dhariwal, et al.
Page
of 35